GLP1R and metabolic dysfunction-associated steatohepatitis: When analysing all these RCTs together, GLP‐1 RA treatment significantly increased the rate of MASH resolution compared to placebo (n = 4 RCTs; pooled random‐effects odds ratio 3.39, 95% CI 2.63–4.36, p < 0.001; I2 = 0%).